These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25348188)

  • 1. Role of oxidative stress on chronic kidney disease progression.
    Putri AY; Thaha M
    Acta Med Indones; 2014 Jul; 46(3):244-52. PubMed ID: 25348188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels.
    Gondouin B; Jourde-Chiche N; Sallee M; Dou L; Cerini C; Loundou A; Morange S; Berland Y; Burtey S; Brunet P; Guieu R; Dussol B
    Nephron; 2015; 131(3):167-74. PubMed ID: 26426087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress in chronic kidney disease.
    Modaresi A; Nafar M; Sahraei Z
    Iran J Kidney Dis; 2015 May; 9(3):165-79. PubMed ID: 25957419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress, anti-oxidant therapies and chronic kidney disease.
    Small DM; Coombes JS; Bennett N; Johnson DW; Gobe GC
    Nephrology (Carlton); 2012 May; 17(4):311-21. PubMed ID: 22288610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidants for chronic kidney disease.
    Jun M
    Nephrology (Carlton); 2013 Aug; 18(8):576-8. PubMed ID: 23865542
    [No Abstract]   [Full Text] [Related]  

  • 6. Oxidative stress - chronic kidney disease - cardiovascular disease: A vicious circle.
    Ravarotto V; Simioni F; Pagnin E; Davis PA; Calò LA
    Life Sci; 2018 Oct; 210():125-131. PubMed ID: 30172705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of extrapolative factors linked with oxidative injury and anti-inflammatory status in chronic kidney disease patients experiencing cardiovascular distress.
    Rasool M; Ashraf MA; Malik A; Waquar S; Khan SA; Qazi MH; Ahmad W; Asif M; Khan SU; Zaheer A; Qaisrani MM; Khan AR; Iqbal A; Raza A; Iram S; Kamran K; Iqbal A; Mustafa MZ; Choudhry H; Zamzami MA; Abdulaal WH; Jamal MS
    PLoS One; 2017; 12(2):e0171561. PubMed ID: 28178330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress is progressively enhanced with advancing stages of CKD.
    Dounousi E; Papavasiliou E; Makedou A; Ioannou K; Katopodis KP; Tselepis A; Siamopoulos KC; Tsakiris D
    Am J Kidney Dis; 2006 Nov; 48(5):752-60. PubMed ID: 17059994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the impact of oxidative stress and some antioxidant therapies on renal damage.
    Tamay-Cach F; Quintana-Pérez JC; Trujillo-Ferrara JG; Cuevas-Hernández RI; Del Valle-Mondragón L; García-Trejo EM; Arellano-Mendoza MG
    Ren Fail; 2016; 38(2):171-5. PubMed ID: 26643776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND; Norris K
    Blood Purif; 2011; 31(1-3):189-96. PubMed ID: 21228589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy.
    Himmelfarb J
    Semin Dial; 2009; 22(6):636-43. PubMed ID: 20017834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention.
    Ardhanari S; Alpert MA; Aggarwal K
    Adv Perit Dial; 2014; 30():40-53. PubMed ID: 25338421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic kidney disease (CKD) as an independent risk factor for cardiovascular disease (CVD)].
    Minami J; Ishimitsu T; Sudo Y; Matsuoka H
    Nihon Rinsho; 2008 Sep; 66(9):1657-63. PubMed ID: 18788391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
    Heine GH; Seiler S; Fliser D
    Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
    Chalmers L; Kaskel FJ; Bamgbola O
    Adv Chronic Kidney Dis; 2006 Oct; 13(4):352-64. PubMed ID: 17045221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease.
    Kendrick J; Chonchol MB
    Nat Clin Pract Nephrol; 2008 Dec; 4(12):672-81. PubMed ID: 18825155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
    Fujii H; Nakai K; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney disease and cardiovascular risk.
    Tonelli M; Pfeffer MA
    Annu Rev Med; 2007; 58():123-39. PubMed ID: 17081079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nontraditional (non-Western pharmaceutical) treatments for chronic kidney disease.
    Gobe GC; Wojcikowski K
    Clin Nephrol; 2020; 93(1):49-54. PubMed ID: 31829927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).
    Formentini I; Bobadilla M; Haefliger C; Hartmann G; Loghman-Adham M; Mizrahi J; Pomposiello S; Prunotto M; Meier M
    Nephrol Dial Transplant; 2012 Oct; 27 Suppl 3():iii81-8. PubMed ID: 22734108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.